| Literature DB >> 16390811 |
Abstract
Much emphasis has been placed on the so-called "biologics" in the treatment of immune disorders within the last few years. Here we discuss the expanding horizon of potential strategies for immunotherapies targeting T lymphocytes as key effectors and regulators of autoimmunity. We review emerging reagents in a variety of animal models and human disorders that may offer new therapeutic options in current or modified iterations.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16390811 DOI: 10.1080/08916930500418136
Source DB: PubMed Journal: Autoimmunity ISSN: 0891-6934 Impact factor: 2.815